A pilot case-control study of second or third-line treatment with cetuximab-containing chemotherapy (cetux-chemo) in patients (pts) with metastatic colorectal cancer (mCRC) who were previously treated with cetux-chemo
Invited conference paper presented and published in conference proceedings

Times Cited
Web of Science0WOS source URL (as at 04/08/2020) Click here for the latest count
Altmetrics Information

Other information
AbstractBackground: This study hypothesized that: (1) pts who had prior exposure to Cetuxchemo in the treatment of mCRC followed by a chemo-break, would respond to retreatment with Cetux at progression (PD), & that the overall response rate (ORR) would be better than those who are treated with chemo alone.

Methods: This study consisted of 2 cohorts. Cohort 1: Prospectively enrolled pts with KRAS-wild type mCRC who had prior Cetux-chemo in 1st/ 2nd line with a best ORR of SD/PR/CR followed by a chemo-break, were re-treated with Cetux-chemo at PD. Cohort 2: A retrospective cohort of KRAS-WT patients (matched by age, sex, no. of sites of metastases (mets), prior Cetux-chemo and prior surgery) who received chemo without any targeted therapy at PD following a chemo-break. The primary objective was to compare the overall response rate (ORR) of cohort 1 & 2, secondary objectives included disease control rate (DCR) & progression free survival (PFS).

Results: 22 eligible pts were enrolled in cohort 1 across two centers in Hong Kong: median age 58yrs, M:F ratio¼ 1:1; site of metastases (mets) ¼ solitary 36.3%, > 1 site 63.7%. None had prior bevacizumab; prior Cetux as 1st line ¼ 77.3% & as 2nd line ¼ 22.7%. In 21 evaluable pts, ORR ¼ 52.4%, SD 33.3%, PD 14.3% & DCR 85.7%. The median OS for cohort 1 ¼ 18.6 ms (95% CI: 11.1-27.1) & 1-yr PFS 36.4%. In cohort 2, 22 matching KRAS-WT patients were identified. The ORR for cohort 2 ¼ 31.8%, DCR 50%, median OS 11ms (95% CI: 4.5-17.1) & 1-yr PFS 22.7%. In a regression analysis which included other prognostic variables (age, sex, prior no. of line of chemo, no. of sites of mets), DCR was the only significantly different factor (odd ratio, OR 6.0, 95% CI: 1.365-26.371, p ¼ 0.018) favouring cohort 1. There was a non-significant trend favouring cohort 1 in ORR (52.4% vs 31.8 %, p ¼ 0.171) and median PFS (8.1ms vs 5.3ms, p ¼ 0.524).

Conclusions: The data suggests that in pts who had prior Cetux-chemo in the 1st or 2nd line treatment of mCRC, re-introduction of Cetux-chemo following a chemo-break was effective in most patients
Acceptance Date30/06/2018
All Author(s) ListHo CS, Cheng AC, Li L, Ho WM, Hui EP, To KF, Tong JHM, Ma BBY
Name of ConferenceEuropean-Society-for-Medical-Oncology Asia Congress
Start Date of Conference23/11/2018
End Date of Conference25/11/2018
Place of ConferenceSingapore
Country/Region of ConferenceSingapore
Proceedings TitleAnnals of Oncology
Title of PublicationANNALS OF ONCOLOGY
Volume Number29
Issue NumberSuppl 9
Article number108P
Pages35 - 35
LanguagesEnglish-United Kingdom
Web of Science Subject CategoriesOncology;Oncology

Last updated on 2020-05-08 at 04:19